|
End-of-day quote
Pakistan S.E.
06/10/2026
|
5-day change | 1st Jan Change | ||
| 314.49 PKR | +2.17% |
|
-0.61% | -19.32% |
Company Valuation: GlaxoSmithKline Pakistan Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 126,403 | 124,132 | 100,155 | - | - |
| Change | - | -1.8% | -19.32% | - | - |
| Enterprise Value (EV) | 126,403 | 124,132 | 100,155 | 100,155 | 100,155 |
| Change | - | -1.8% | -19.32% | 0% | 0% |
| P/E | 19.3x | 12.4x | 9.47x | 7.87x | 7.01x |
| PBR | - | 3.69x | 2.63x | 2.23x | 1.93x |
| PEG | - | 0.2x | 1.72x | 0.4x | 0.6x |
| Capitalization / Revenue | - | 1.88x | 1.46x | 1.34x | 1.22x |
| EV / Revenue | - | 0x | 1.46x | 1.34x | 1.22x |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | 17 | 18.04 | 20.81 | 23 |
| Rate of return | - | 4.36% | 5.74% | 6.62% | 7.31% |
| EPS 2 | 20.52 | 31.48 | 33.21 | 39.96 | 44.85 |
| Distribution rate | - | 54% | 54.3% | 52.1% | 51.3% |
| Net sales 1 | - | 65,901 | 68,813 | 74,577 | 81,779 |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Net income 1 | 6,536 | 10,025 | 10,490 | 12,420 | 14,268 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 396.91 | 389.78 | 314.49 | 314.49 | 314.49 |
| Nbr of stocks (in thousands) | 318,467 | 318,467 | 318,467 | - | - |
| Announcement Date | 24/03/25 | 26/03/26 | - | - | - |
1PKR in Million2PKR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 9.27x | - | - | 5.86% | 354M | |
| 32.46x | 11.79x | 23.8x | 0.61% | 1,019B | |
| 28.13x | 6.24x | 17.86x | 2.11% | 610B | |
| 33.64x | 7.86x | 16.24x | 2.61% | 470B | |
| 101.52x | 5.7x | 24.22x | 2.45% | 344B | |
| 18.95x | 4.61x | 11.45x | 2.87% | 336B | |
| 19.74x | 5.16x | 12.75x | 3.1% | 266B | |
| 19.84x | 4.13x | 11.77x | 2.15% | 241B | |
| 25.45x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.74x | 6.39x | 24.95x | 2.28% | 179B | |
| Average | 24.53x | 6.50x | 17.21x | 2.65% | 368.32B | |
| Weighted average by Cap. | 31.25x | 7.60x | 18.53x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- Valuation GlaxoSmithKline Pakistan Limited
Select your edition
All financial news and data tailored to specific country editions
